- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Fund Finance
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Leveraged Finance
- Mergers and Acquisitions (M&A)
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations
- Private Equity
- Public Companies
- Real Estate
- Structured Finance and Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- Innovation Protection
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Antitrust
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Innovation Protection
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy Transition
- Energy
- Financial Services
- Food and Beverage
- Higher Education
- Life Sciences and Healthcare
- Technology
- Artificial Intelligence (AI) and Machine Learning
- Buy American
- Crisis Management
- Doing Business in Latin America
- Environmental Agenda
- Environmental, Social and Governance (ESG)
- Focus on Women's Health
- Russia/Ukraine
- Special Purpose Acquisition Companies (SPACs)
- Careers
- News & Insights
- About
- Languages
M. Sean Royall
News 12 results
In the News · Source: Law360
In the News · Source: Thomson Reuters Westlaw Today
January 24, 2025
Westlaw Today interviews Sean Royall, who discusses antitrust enforcement under the second Trump administration
Recognition
December 11, 2024
King & Spalding Again Recognized on Global Competition Review’s GCR 100 List
In the News · Source: Law360 Pulse
November 25, 2024
Law360 Pulse profiles K&S’s move to a 25,000 square-foot office space at The Link at Uptown in Dallas
Events 3 results
Webinar
July 17, 2024
Government Attack on Three Fronts: Pharmaceutical and Medical Device Industries Face Continual Pricing Pressure
Speaking Engagement
May 17, 2024
Sean Royall to Speak at the Federalist Society’s Third Annual In-House Counsel Network Conference
Conference
November 7, 2023
Pharmaceutical University 2023
Insights 7 results
Client Alert
April 16, 2025
DOJ/FTC Initiatives Seek Public Comment on Anticompetitive Government Regulations
Client Alert
February 6, 2025
What is the Future of Antitrust Enforcement Under Trump 2.0?
Client Alert
April 24, 2024
FTC Issues Near-Total Ban on Non-Competes in Final Rule, with a Narrow Exception for Existing Agreements with “Senior Executives”
Client Alert
January 23, 2024
FTC Proposes Stricter Children’s Privacy Rules in First COPPA Update since 2013